ALK-Abelló
212.60 DKK
-0.19 %
Less than 1K followers
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for ALK-Abelló
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,313.0 | 1,499.0 | 5,537.0 | 1,522.0 | 1,527.0 | 1,530.0 | 1,733.0 | 6,312.0 |
| EBITDA | 369.0 | 281.0 | 1,363.0 | 540.0 | 450.0 | 510.0 | 482.0 | 1,982.0 |
| EBIT | 306.0 | 205.0 | 1,091.0 | 469.0 | 375.0 | 423.0 | 387.0 | 1,654.0 |
| EBIT-% | 23.3 % | 13.7 % | 19.7 % | 30.8 % | 24.6 % | 27.6 % | 22.3 % | 26.2 % |
| Profit before taxes | 281.0 | 198.0 | 1,057.0 | 473.0 | 350.0 | 419.0 | 393.0 | 1,635.0 |
| Net income | 212.0 | 170.0 | 815.0 | 354.0 | 263.0 | 314.0 | 266.0 | 1,197.0 |